Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.
Are we ready to consider tissue agnostic treatment options in Solid Tumors
Oncology Published 2 years ago
Content
Oncology
4m 31s
Molecular Diagnostics for Glioma
Published 15 Sep 2022
Purpose of molecular testing is to subclassify the gliomas and identify novel targets for pharmacological interventions. New WHO classification of CNS tumors has incorporated both histology and molecular features to define including glioblastoma, IDH-wildtype and glioblastoma, IDH-mutant; diffuse midline glioma to name a few. ATRX status is emerging as one of the critical markers for molecular classification of gliomas.
